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“Much Ado About Nothing?”*Bradley H. Strauss, MD, PHD, Mony Shuvy, MDC oronary stent implantation has become themainstay of percutaneous revascularizationin patients with stable coronary artery dis-
ease (CAD) and acute coronary syndromes (ACS).
Bare metal stents (BMS) were widely adopted after
they were demonstrated to decrease restenosis and
acute vessel occlusion compared with balloon angio-
plasty, although the thrombosis risk was <1% and
usually occurred within the ﬁrst month after implan-
tation (1).SEE PAGE 16The introduction of ﬁrst-generation drug-eluting
stents (DES) dramatically decreased the rate of
restenosis, and the use of DES in contemporary
practice became the standard of care for most pa-
tients. However, concerns were raised regarding the
safety of ﬁrst-generation DES and the associated
increased risk of stent thrombosis (ST) beyond the
traditional 1-month timeframe (2). These concerns
were even more pronounced in patients presenting
with ST-segment elevation myocardial infarction
(STEMI), who are at an even higher risk of ST com-
pared with patients with stable CAD (3). Autopsy
specimens after cardiac death have shown a greater
number of uncovered stent struts in patients
with ﬁrst-generation DES compared with BMS (4).
Delayed healing, characterized by incomplete en-
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paper to disclose.at angioscopy, was evident several months after
ﬁrst-generation DES implantation, but not in BMS
(5). Several procedural factors including small vessel
size, long stents, suboptimal stent expansion, re-
sidual dissection, the presence of thrombus, and
slow coronary ﬂow may contribute to ST. In addi-
tion, speciﬁc predictors of ST (large thrombotic
burden and suboptimal stent expansion to avoid
the risk of no-reﬂow) are more common in STEMI
patients (1).
The current American College of Cardiology
Foundation/American Heart Association guidelines
for STEMI management recommend stents in pri-
mary percutaneous coronary intervention, but does
not distinguish between BMS or DES use. The
guidelines state that ﬁrst-generation DES do not in-
crease early or late ST, but controversy still persists
regarding increased very late ST rates with ﬁrst-
generation DES, which may not be the case with
the newer generation cobalt chromium everolimus-
eluting stents (6).
In this issue of the Journal, Sarno et al. (7) have
advanced the ﬁeld of STEMI care with their report on
the incidence of ST in 34,147 patients with STEMI
enrolled in the SCAAR (Swedish Coronary Angiog-
raphy and Angioplasty Registry). They compared
rates of early (1 month), late (#1 year), and very late
(>1 year) ST, as well as mortality rates in 3 groups
based on the stent-type deployed.
After adjusting for baseline characteristics using
propensity-scoring models, the authors showed
a lower risk for ST (early and late) in patients
treated with DES (ﬁrst- and second-generation)
compared with BMS. Very late ST was higher in
ﬁrst-generation DES compared with BMS, whereas
there were no statistical differences between BMS
and second-generation DES. In the ﬁrst year of
follow-up, ST rates were 1.5% for BMS, 1.1% for
Strauss and Shuvy J A C C V O L . 6 4 , N O . 1 , 2 0 1 4
Stent Thrombosis Following DES in STEMI J U L Y 8 , 2 0 1 4 : 2 5 – 7
26ﬁrst-generation DES, and 0.9% for second-
generation DES. However, between the ﬁrst and
the third years, the absolute rate of ST was 2-fold
higher in the ﬁrst-generation DES group compared
with the BMS group. A second, potentially more
clinically important, observation from the study was
a signiﬁcantly lower mortality rate in patients
treated with DES (either ﬁrst- or second-generation)
compared with patients treated with BMS; these
differences were evident early after the stent
procedure.
ST is a rare event, requiring studies with large
numbers of patients. Most randomized clinical trials
are underpowered for this purpose, and patient
registries, such as the SCAAR, are essential for
the evaluation of ST in the STEMI population. The
overall sample size (n ¼ >34,000) of this “all-
comers” national STEMI registry, along with its
large number of patients included in each of the 3
groups, allows for meaningful comparisons. Second-
generation DES have theoretical advantages over
ﬁrst-generation DES because of the thin-strut de-
sign, reduced polymer layer, and, potentially, the
use of a novel drug. The SCAAR ST results are also
consistent with several recently published large
meta-analyses of STEMI patients treated with DES or
BMS (8,9).
However, the SCAAR results have several limita-
tions that need to be considered. The study lacks
important clinical data, such as the duration of dual-
antiplatelet therapy (DAPT) in the various groups.
Differences in antiplatelet agents and procedural
anticoagulation between study groups also may have
contributed to the outcomes. Ticagrelor, a potent
antiplatelet agent shown to be more efﬁcacious in
ACS patients with lower ST compared with clopidog-
rel (10), was more often used in the ﬁrst-generation
DES group, whereas clopidogrel was used more in
the BMS group. Bivalirudin was used more in DESpatients, whereas glycoprotein IIb/IIIa was predomi-
nant in BMS patients.
Also, the BMS patients in the propensity analysis
seem to have been mainly drawn from the early phase
of the study (2007 to 2009), which may potentially
bias the comparison with the patients treated with
second-generation DES that predominate in the latter
stages of the study.
Finally, the differences in mortality data between
BMS patients and ﬁrst- and second-generation DES
patients in the current study are intriguing, but
should raise concerns about unmeasured selection
bias in the study despite the propensity analysis.
To date, no prospective, randomized studies have
shown differences in mortality between DES and
BMS, although an “all-comers” Ontario registry
study also showed signiﬁcant differences in sur-
vival for ﬁrst-generation DES patients in a propen-
sity analysis (11). Additional conﬁrmatory data are
needed.
The SCAAR results are reassuring and should
mitigate concerns about late and very late ST
with second-generation DES in STEMI patients.
More recent data suggesting the need for only a
3-month duration of DAPT for second-generation
DES (12) may even further extend the use of
these DES in STEMI patients because current
guidelines require that DES must not be implanted
in patients unable to tolerate or comply with a 1-
year course of DAPT (6). As our daily practices
evolve with this new knowledge, we expect that
future STEMI guidelines for DES also will need to
be updated.
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